personalized medicine

Genome Management, Genome Factories and Other Audacious Goals Discussed at PMWC 2014

On January 27-28,  thought leaders from across multiple industries assembled at the Computer History Museum in Silicon Valley to discuss key themes in personalized medicine at the Personalized Medicine World Conference 2014 (PMWC).

Personalized Medicine for Pain with Simon Tate, Convergence Pharma


Simon Tate, Chief Scientific Officer, Convergence Pharmaceuticals

Bio and Contact Info

Listen (6:09) Sodium channel blockers and the Nav1.7 protein

Listen (4:17) How will your product compare with other pain meds?

Listen (5:06) Targeted clinical trials

Listen (3:36) A huge unmet medical need

Listen (4:28) Learning from the Vioxx scandal

Listen (2:31) Thoughts on marijuana use for pain

Did you know that you may have a gene which makes you experience more or less pain? Pain, that uncomfortable sensory experience we get when we stub our toe or suffer a cut, is the most common reason why we visit the doctor in America. It’s role is to send an alarm signal that something is wrong. Yet many people experience pain differently and at different levels based on their genetic makeup.

According to today's guest, Simon Tate, CSO for Convergence Pharmaceuticals, the area of pain presents a huge opportunity for personalized medicine.

His company's new technology acts by blocking sodium channels, conductive proteins that are part of the nervous system. Those born with a certain mutation of the SCN9A gene have "more active" sodium channels, and the clinical trials the company is running targets this population. The more active the channel, the more active becomes the drug molecule. According to Tate, sodium channel blockers have the potential to create a new paradigm in the treatment of chronic pain.

"Pain can be forgotten," says Simon about pain research. "In the US there is 50 times more funding going into cancer than into pain. . . . There's a huge unmet need here."

How is Convergence going about their clinical trials? And what can they learn from the Vioxx scandal? Simon answers these questions and more in today's show.

Podcast brought to you by: Chempetitive Group - "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."

CoDx the Only Way Forward for Big Pharma: John Palma, Roche Molecular


John Palma, Director of Medical Affairs, Roche Molecular

Bio and Contact Info

Listen (6:54) On demonstrating clinical value of CoDx

Listen (4:45) What is the lead time for CoDx from discovery to market?

Listen (4:11) International considerations

Listen (4:38) CoDx the only way forward for big pharma

Listen (6:54) Are you seeing more companies opt for the CoDx way?

John Palma is the Director of Clinical and Scientific Affairs at Roche Molecular. His job is to demonstrate the clinical value of the companion diagnostics that are developed at Roche. In today's interview, John gives us a "view from the trenches."

How does his team decide when to move forward on a promising biomarker? What is the lead time for CoDx compared to Rx? What are the considerations in going international? What does success look like? John addresses some practical realities for those moving pharma in the direction of personalized medicine. Will a CoDx business strategy be able to save big pharma? John says it's the only way forward.

Podcast brought to you by: Myraqa Clinical Research: The CRO for Point of Care and PMA Diagnostics.

FDA Makes Two Strong Moves in Direction of Personalized Medicine

Two statements by the FDA this week--one a letter to the DTC genomics company, 23andMe, the other a press release announcing the clearance of Illumina's MiSeq platform for a diagnostic assay--signal an agency on the move.

Disruption, Dissent, and Diversity at Burrill's PM Meeting

Last week Burrill and Co. put on their 9th annual Personalized Medicine Conference.  The Burrill meetings are known for straight talk on business matters, in depth panel discussions, working lunches, star speakers, and of course, Steve Burrill.  While this year’s meeting followed in that path, there was more diversity, more disagreement, more complexity. 

IPOs, and more IPOs

Burrill kicked off his usual state of the industry talk with a caveat that echoed throughout the show,  “healthcare doesn’t follow normal laws of economics.”

Quality Is the Key, Says Veteran of Personalized Medicine

Guest: Dr. Larry Marton, Program Chair, PMWC

Bio and Contact Info

Chapters: (Advance the marker)

0:40 Building one of the first molecular diagnostics labs at UCSF

6:47 Where are we at with personalized medicine today?

11:27 What can we do to better quality assurance in the industry?

19:01 Using PMWC as a neutral place for dialogue between disparate groups

23:47 If you practice medicine better than the community, you can be in trouble

29:14 What can those in the industry do to better engage the medical community?

Our guest today has been focused on personalized medicine since before it was called that. Larry Marton is the former chair of the Department of Laboratory Medicine at UCSF. Helping to form the department back in the late 70's, Larry and his colleagues set out to transform a standard clinical laboratory into a place for cutting edge molecular research, a place where basic research could be done and translated into medical practice.

Today he's retired from UCSF, but "busier than ever before." He serves on various boards and is the program chair for the Personalized Medicine World Conference which takes place each January in Mountain View, CA. Anyone who has been to this conference knows the depth and breadth of Larry's contacts and influence in the industry. He says the PMWC is an important conference because it plays the role of "neutral broker" between the various stakeholders in the field: entrepreneurs, researchers, investors, regulators, physicians, and patients.

Larry's core message is that we must improve the quality of new clinical tests which have been translated from research. It is the key to demonstrating clinical relevance, he says. There are issues with sampling, with analytics, and with compliance. What can those in the industry do to better the quality assurance? And how can the industry better engage the medical community? A veteran shares his insights.

Podcast brought to you by: Chempetitive Group - "We love science. We love marketing. We love the idea of combining the two to make great things happen for your marketing communications."

Garry Nolan: Trailblazing Single Cell Analysis

Podcast brought to you by: Fluidigm - The leader in single-cell genomics and maker of the C1™ Single-Cell Auto Prep System. The path less traveled just go easier.


Garry Nolan, PhD, Professor of Microbiology and Immunology, Stanford University School of Medicine Bio and Contact Info

Listen (6:41) Why is the focus on the single cell so important?

Listen (5:18) Low hanging fruit from bulk analysis already picked

Listen (6:29) What has been the response to your work?

Listen (6:25) Commercializing work as diagnostics at Nodality

Listen (6:38) Biggest challenge is to simplify

Making a big decision several years ago that his lab would have the single focus on the single cell, Gary Nolan has become a global leader in a new discipline. In today's show, he shares his conviction that the next frontier in biology is to expand the number of parameters wherein the individual cell can be studied. "The low hanging fruit from bulk analysis has already been picked," he says. Gary is a founder of two companies, Rigel Pharma (publicly traded) and Nodality, wherein his research is being commercialized. Is 2013 the year of single cell genomics, we ask this trailblazer.

Eric Topol and His "Creative Destruction"

Podcast brought to you by: The Burrill and Buck Aging Conference Explore how innovative approaches from regenerative medicine to digital health stand to change our notion of what it means to grow old.


Eric Topol, MD, Cardiologist, Genetic Researcher, and Technologist Bio and Contact Info

Listen (6:22) Patient stories heard at Future of Genomic Medicine Conference

Listen (4:34) Medical community's response to book

Listen (6:02) "I just wish I could go back and start medical school again"

Listen (4:30) Eradicate fee for service

Listen (3:05) Craig Venter: Quality of sequencing has gone down

Listen (4:29) "De"personalized medicine?

Listen (0:58) Excited about rollout of sensors

Eric Topol joins us to discuss what was perhaps the most talked about book in the life sciences in 2012, his "The Creative Destruction of Medicine." In his book, Topol tells of the now arriving era of individualized medicine and the rise of "homo digitus," or digital man. In today's show, Topol dives into some key topics from the book such as how to deal with misaligned incentives in healthcare. "I just wish I could go back and start medical school again because this is truly an era . . a renaissance, an enlightenment in the medical space," says Topol when asked about what he advises young people.

Dr. Topol recently hosted the Future of Genomic Medicine Conference at The Scripps in San Diego, and he begins the interview giving some highlights of patient stories.

Highlights of the 5th Personalized Medicine World Conference

This week the always spectacularly organized Tal Behar and her team put on the 5th annual Personalized Medicine World Conference (#PMWCintl). I want to mention a couple highlights from the conference: prenatal diagnostics and cell profiling.

Prenatal Diagnostics

New to Mendelspod?

We advance life science research, connecting people and ideas.
Register here to receive our newsletter.

or skip signup